Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome)

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue SUPPL. 1, 1999, Pages 231-249

  Laron, Z ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

GH insensitivity; GH receptor defect; GH resistance; IGF I deficiency; Laron syndrome

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; SOMATOMEDIN;

ADULTHOOD; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; GENE DELETION; GROWTH HORMONE BLOOD LEVEL; GROWTH RETARDATION; HORMONE RESISTANCE; HUMAN; INFANCY; LARON SYNDROME; MISSENSE MUTATION; OBESITY; PATHOGENESIS; SEXUAL MATURATION;

ABNORMALITIES, MULTIPLE; CARRIER PROTEINS; DRUG RESISTANCE; ENDOCRINE SYSTEM; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MALE; MUSCULOSKELETAL ABNORMALITIES; RECEPTORS, SOMATOTROPIN; SEXUAL MATURATION; SYNDROME;

EID: 0033001026     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (99)

1. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-155.
2. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 883-894.
3. Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Phys 1969; 82: 129-138.
4. Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses. J Clin Endocrinol Metab 1971; 33: 332-342.
5. Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab 1973; 37: 819-821.
6. Eshet R, Laron Z, Brown M, Arnon R. Immunological behaviour of hGH from plasma of patients with familial dwarfism and high IR-hGH in a radioimmunoassay system using the cross-reaction between hGH and HCS. Horm Metab Res 1974; 6: 79-81.
7. Jacobs LS, Sneid DS, Garland JT, Laron Z, Daughaday WH. Receptor-active growth hormone in Laron dwarfism. J Clin Endocrinol Metab 1976; 43: 403-407.
8. Eshet R, Peleg S, Josefsberg Z, Laron Z. Characterization of hGH from patients with LTD by a human liver radioreceptor assay (RRA). Pediatr Res 1981; 15: 89 (abst).
9. Eshet R, Laron Z, Pertzelan A, Dintzman M. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. Isr J Med Sci 1984; 20: 8-11.
10. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Woods WI. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537-543.
11. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989; 86: 8083-8087.
12. Laron Z. Laron syndrome - Primary growth hormone resistance. In: Jameson JL, ed. Contemporary Endocrinology: Hormone Resistance Syndromes. Totowa, NJ: Humana Press, 1999; 17-37.
13. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underwood L. Classification of growth hormone insensitivity syndrome. J Pediatr 1993;122: 241.
14. Elders MJ, Garland JT, Daughaday WH, Fisher DA, Whitney JE, Hughes ER. Laron's dwarfism: Studies on the nature of the defect. J Pediatr 1973; 83: 253-263.
15. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goosens M. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 1989; 321: 989-995.
16. Laron Z. Laron syndrome: from description to therapy. Endocrinologist 1993; 3: 21-28.
17. Pertzelan A, Adam A, Laron Z. Genetic aspects of pituitary dwarfism due to absence of biological activity of growth hormone. Isr J Med Sci 1968;4: 895-900.
18. Laron Z, Pertzelan A, Karp M, Keret R, Eshet R, Silbergeld A. Laron syndrome - A unique model of IGF-I deficiency. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 3-23.
19. Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993; 29: 757-763.
20. Laron Z. Laron type dwarfism (hereditary somatomedin deficiency): a review. In: Frick P, Von Harnack GA, Kochsiek GA, Prader A, eds. Advances in Internal Medicine and Pediatrics. Berlin-Heidelberg: Springer-Verlag, 1984; 117-150.
21. Laron Z, Klinger B, Grunebaum M. Laron type dwarfism. Special feature - Picture of the month. Am J Dis Child 1991; 145: 473-474.
22. Scharf A, Laron Z. Skull changes in pituitary dwarfism and the syndrome of familial dwarfism with high plasma immunoreactive growth hormone. A roentgenologic study. Horm Metab Res 1972; 4: 93-97.
23. Konfino R, Pertzelan A, Laron Z. Cephalometric measurements of familial dwarfism and high plasma immunoreactive growth hormone. Am J Orthodont 1975; 68: 196-201.
24. Laron Z. Prismatic cases: Laron syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526-1531.
25. Arad I, Laron Z. Standards for upper/lower body segment/sitting height - subischial leg length, from birth to 18 years in girls and boys. In: Proceedings 1st International Congress Auxology, Rome, 1977. Milan: Centro Auxologia Italiano di Piancavallo, 1979; 159-164.
26. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68: 768-770.
27. Laron Z, Sarel R. Penis and testicular size in patients with growth hormone insufficiency. Acta Endocrinol 1970; 63: 625-633.
28. Laron Z, Sarel R, Pertzelan A. Puberty in Laron type dwarfism. Eur J Pediatr 1980; 134: 79-83.
29. Pertzelan A, Lazar L, Klinger B, Laron Z. Puberty in 15 patients with Laron syndrome: a longitudinal study. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 27-33.
30. Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm Res 1993; 40: 16-22.
31. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: Preliminary results. Clin Endocrinol 1994; 41: 631-638.
32. Brat O, Ziv I, Klinger B, Avraham M, Laron Z. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome. Horm Res 1997; 47: 45-48.
33. Laron Z, Anin S, Klipper-Aubach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-1261.
34. Laron Z, Lazar L, Klinger B. Growth hormone, insulin-like growth factor I and brain growth and function. In: Castells S, Wisniewski KE, eds. Growth Hormone Treatment in Down's Syndrome. Chichester: Wiley and Sons, 1993; 151-161.
35. Frankel JJ, Laron Z. Psychological aspects of pituitary insufficiency in children and adolescents with special reference to growth hormone. Isr J Med Sci 1968; 4: 953-961.
36. Galatzer A, Aran O, Nagelberg N, Rubitzek J, Laron Z. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 53-60.
37. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome), before and during insulin-like growth factor I treatment. Metabolism 1995; 44 (Suppl 4): 113-118.
38. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron syndrome (primary insulin-like growth factor-I [IGF-I] deficiency) and effect of IGF-I replacement therapy. J Pediatr Endocrinol Metab 1997; 10 (Suppl 1): 105-115.
39. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994; 8: 684-688.
40. Klinger B, Jensen LT, Silbergeld A, Laron Z. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996; 45: 423-429.
41. Keret R, Pertzelan A, Zeharia A, Zadik Z, Laron Z. Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Isr J Med Sci 1988; 34: 75-79.
42. Laron Z, Pertzelan A, Doron M, Assa S, Keret R. The effect of dihydrosomatostatin in dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res 1977; 9: 338-339.
43. Laron Z, Klinger B, Jensen LT, Erster B. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991; 35: 145-150.
44. Eshet R, Dux Z, Silbergeld A, Koren R, Klinger B, Laron Z. Erythrocytes from patients with low serum concentrations of IGF-I have an increase in receptor sites for IGF-I. Acta Endocrinol (Copenh) 1991; 125: 354-358.
45. Eshet R, Klinger B, Silbergeld A, Laron Z. Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS). Regul Peptides 1993; 48: 233-239.
46. Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301-304.
47. Laron Z, Suikkari AM, Klinger B, Silbergeld A, Pertzelan A, Seppala M, Koivisto VA. Growth hormone and insulin-like growth factor regulate insulin-like growth factor binding protein in Laron type dwarfism, growth hormone deficiency and constitutional growth retardation. Acta Endocrinol 1992; 127: 351-358.
48. Klinger B, Ionesco A, Anin S, Laron Z. Effect of insulin-like growth factor I on the thyroid axis in patients with Laron-type dwarfism and healthy subjects. Acta Endocrinol (Copenh) 1992; 127: 515-519.
49. Silbergeld A, Klinger B, Schwartz H, Laron Z. Serum prolactin in patients with Laron type dwarfism: effect of insulin-like growth factor I. Horm Res 1992; 37: 160-164.
50. Laron Z, Karp M. Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immunoreactive growth hormone (Laron type dwarfism). In: Podolsky S, Wiswanathan M, eds. Secondary Diabetes: The Spectrum of the Diabetic Syndrome. New York: Raven Press, 1980; 363-371.
51. Bass SH, Mulkerrin MG, Wells JA. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci USA 1991; 88: 4498-4502.
52. Barton DE, Foellmer BE, Woods WI, Francke U. Chromosome mapping of the growth hormone receptor gene in man and mouse. Cytogenet Cell Genet 1989; 50: 137-141.
53. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993; 74: 237-244.
54. Horseman NS. Editorial: Famine to feast - growth hormone and prolactin signal transducers. Endocrinology 1994; 135: 1289-1291.
55. Daughaday WH. Are there direct, non-IGF-I-mediated effects of hGH? In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 338-345.
56. Kelly PA, Goujon L Sotiropoulos A, Dinerstein H, Esposito N, Edery M, Finidori J, Postel-Vinay MC. The GH receptor and signal transduction. Horm Res 1994; 42: 133-139.
57. de Vos AM, Ultsch M, Kossiakioff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306-312.
58. Amselem S, Sobrier M-L, Dastot F, Duquesnoy P, Duriez B, Goossens M. Molecular basis of inherited growth hormone resistance in childhood. In: Ross RJM, Savage MO, eds. Growth Hormone Resistance. Ballière's Clin Endocrinol Metab 1996; 10: 353-369.
59. Amselem S, Sobrier ML, Duquesnoy P, Rappaport R, Postel-Vinay MS, Gourmelen M, Dallapiccola B, Goossens M. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. J Clin Invest 1991; 87: 1098-1102.
60. Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab 1997; 82: 435-437.
61. Berg MA, Peoples R, Perez-Jurado L, Guevara-Aguirre J, Rosenbloom AL, Laron Z, Milner RDG, Francke U. Receptor mutations and haplotypes in growth hormone receptor deficiency: a global survey and identification of the Ecuadorean E180 splice mutation in an oriental Jewish patient. Acta Paediatr 1994; Suppl 399: 112-114.
62. Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier ML, Valleix, S. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet 1993; 2: 355-359.
63. Counts DR, Cutler GB. Growth hormone insensitivity syndrome due to point deletion and frame shift in the growth hormone receptor. J Clin Endocrinol Metab 1995; 80: 1978-1981.
64. Berg MA, Argente J, Chernausek S, Gracia R, Guevara-Aguirre J, Hopp M, Perez-Jurado L, Rosenbloom AL, Toledo SPA, Francke U. Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 1993; 52: 998-1005.
65. Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U. Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutat 1992; 1: 124-134.
66. Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, Stein S, Eidson M, Parks JS, Cleveland W. Clinical, biochemical and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab 1997; 82: 444-451.
67. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997; 10: 265-274.
68. Woods KA, Fraser NC, Postel-Vinay MC, Dusquenoy P, Savage MO, Clark AJL. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996; 81: 1686-1690.
69. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M, Amselem S. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J 1994; 13: 1386-1395.
70. Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab 1993; 76: 54-59.
71. Daughaday WH, Trivedi B. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proc Natl Acad Sci USA 1987; 84: 4636-4640.
72. Baumann G, Shaw MA, Winter RJ. Absence of plasma growth hormone-binding protein in Laron-type dwarfism. J Clin Endocrinol Metab 1987; 65: 814-816.
73. Duquesnoy P, Sobrier ML, Amselem S, Goossens M. Defective membrane expression of human growth hormone (GH) receptor causes Laron-type GH insensitivity syndrome. Proc Natl Acad Sci USA 1991; 88: 10272-10276.
74. Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 1986; 77: 1817-1823.
75. Baumann G, Stolar MN, Amburn K, Barsano CP, DeVries BC. A specific GH-binding protein in human plasma: Initial characterization. J Clin Endocrinol Metab 1986; 62: 134-141.
76. Silbergeld A, Lazar L, Erster B, Keret R, Tepper R, Laron Z. Serum growth hormone binding protein activity in healthy neonates, children and young adults - correlation with age, height and weight. Clin Endocrinol 1989; 31: 295-303.
77. Laron Z, Klinger B, Erster B, Silbergeld A. Serum GH binding protein activity identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol 1989; 121: 603-608.
78. Silbergeld A, Keret R, Selman-Almonte A, Klinger B, Laron Z. Serum growth hormone binding protein in Laron syndrome patients and their relatives. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 153-159.
79. Woods KA, Savage MO. Laron syndrome: typical and atypical forms. In: Ross RJM, Savage MO, eds. Growth Hormone Resistance. Ballière's Clin Endocrinol Metab 1996; 10: 411-420.
80. Abramovici A, Josefsberg Z, Mimouni M, Liban E, Laron Z. Histopathological features of the skin in hypopituitarism in Laron type dwarfism. Isr J Med Sci 1983; 19: 515-519.
81. Laron Z. Primary IGF-I deficiency due to primary growth hormone resistance (Laron syndrome). In: Merimee TJ, Laron Z, eds. Growth Hormone, IGF-I and Growth. New Views of Old Concepts. Tel Aviv-London: Freund Publ. House, Ltd., 1996; 199-215.
82. Guevarra-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond FB Jr, Rosenfeld RG. Growth hormone receptor deficiency in Ecuador; clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 1993; 76: 417-423.
83. Yordam N, Kandemir N, Erkul I, Kurdoglu S, Hatun S. Review of Turkish patients with growth hormone insensitivity (Laron type). Eur J Endocrinol 1995; 133: 539-542.
84. Maheshwari HG, Clayton PE, Mughal Z, Price DA, Norman M. Laron type dwarfism: the GH-BP positive phenotype. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. Pediatric and Adolescent Endocrinology, Vol. 24. Basel-New York: Karger, 1993; 160-166.
85. Desai M, Choksi C, Colaco P, Ambadkar M. Familial growth hormone deficiency (GHD) and growth hormone insensitivity (GHI) in Indian children. Horm Res 1997; 48 (Suppl 2): 90 (abst #442).
86. Kastrup KW, Andersen H, Hanssen KF. Increased immunoreactive plasma and urinary growth hormone in growth retardation with defective generation of somatomedin A (Laron's syndrome). Acta Paediatr Scand 1975; 64: 613-318.
87. Van den Brande JL, DuCaju MVL, Visser HKA, Schopman W, Hacheng WHL, Degenhart H. Primary somatomedin deficiency. Arch Dis Child 1974; 49: 297-304.
88. Kržišnik C, Battelino T. Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report). J Pediatr Endocrinol Metab 1997; 10: 443-447.
89. Rosenbloom AL, Berg MA, Kasatkina EP, Volkova TN, Skorobogatova W, Sokolovskaya VN, Francke U. Severe growth hormone insensitivity (Laron syndrome) due to nonsense mutation of the GH receptor in brothers from Russia. J Pediatr Endocrinol Metab 1995; 8: 159-166.
90. Igarashi N, Sato T. A case of dwarfism with severely reduced activity of growth hormone binding protein. Nippon Naibunpi Gakkai Zasshi 1991; 383: 121-124.
91. Merimee TJ, Hall J, Rabinowitz D, McKusick VA, Rimoin DL. An unusual variety of endocrine dwarfism: subresponsiveness to growth hormone in a sexually mature dwarf. Lancet 1968; ii: 191-193.
92. McCoy EE, Bala RM. Somatomedin deficiency (Laron type) dwarfism in Eskimo children. Clin Res 1978; 26: 845A (abstr).
93. Vesterhus P. Genetic defects and therapy in Laron syndrome and similar conditions. Tidsskr Nor Laegeforen 1997; 117: 948-951.
94. Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 1998; 83: 2554-2561.
95. Rosenbloom AL, Guevara-Aguirre J. Lessons from the genetics of Laron syndrome. Trend Endocrinol Metab 1998; 9: 276-282.
96. Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: A controlled study in a genetically homogeneous population. J Clin Endocrinol Metab 1998; 83: 1953-1958.
97. Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/ binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 1997; 94: 13215-13220.
98. Laron Z, Desai M, Silbergeld A. Girls with Laron syndrome having positive growth hormone binding protein (GHBP) are less retarded in height than those lacking GHBP. J Pediatr Endocrinol Metab 1997; 10: 305-307.
99. Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay M-C, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82: 3529-3535.